Cargando…
Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has been a clinical breakthrough for pediatric B-cell acute lymphoblastic leukemia (B-ALL), and loss of the CD19 target antigen on leukemic cells represents a major mechanism of relapse. Previous studies have observed CD19 mutations speci...
Autores principales: | Chen, Gregory M., Chen, Chia-Hui, Perazzelli, Jessica, Grupp, Stephan A., Barrett, David M., Tan, Kai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808313/ https://www.ncbi.nlm.nih.gov/pubmed/36255409 http://dx.doi.org/10.1158/2326-6066.CIR-22-0095 |
Ejemplares similares
-
Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy
por: Tang, Jack Pengfei, et al.
Publicado: (2022) -
CRASH-IT Switch Enables Reversible and Dose-Dependent Control of TCR and CAR T-cell Function
por: Sahillioglu, Ali Can, et al.
Publicado: (2021) -
Oxidative Phosphorylation Fueled by Fatty Acid Oxidation Sensitizes Leukemic Stem Cells to Cold
por: Griessinger, Emmanuel, et al.
Publicado: (2023) -
Radiofrequency Ablation Remodels the Tumor Microenvironment and Promotes Neutrophil-Mediated Abscopal Immunomodulation in Pancreatic Cancer
por: Faraoni, Erika Y., et al.
Publicado: (2023) -
PBRM1 Inactivation Promotes Upregulation of Human Endogenous Retroviruses in a HIF-Dependent Manner
por: Zhou, Mi, et al.
Publicado: (2022)